The Risk of Hypothyroidism With the Use of <scp>GLP</scp> ‐1 Receptor Agonists in Saudi Arabia
In this real-world analysis, GLP-1RA use was not associated with an increased incidence of hypothyroidism compared to DPP-4is. Findings were consistent across sensitivity and subgroup analyses. Although findings do not suggest a short-term risk, longer-term studies are warranted to further evaluate thyroid safety.
Authors
- Yasser Albogami (ORCID: https://orcid.org/0000-0002-2816-6526)
- Raseel Alroba
- Adel Alrwisan (ORCID: https://orcid.org/0000-0002-9422-7390)
- Omar A. Alshaya (ORCID: https://orcid.org/0000-0002-2244-0491)
- Ohoud Almadani (ORCID: https://orcid.org/0000-0002-6246-0841)
- Almaha Alfakhri
Institutions
- King Saud University (SA)
- Saudi Arabian Monetary Authority (SA)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/pds.70315
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00